Nanocarrier-Mediated Delivery of MicroRNAs for Fibrotic Diseases

Mol Diagn Ther. 2024 Jan;28(1):53-67. doi: 10.1007/s40291-023-00681-y. Epub 2023 Oct 28.

Abstract

MicroRNAs (miRNAs) are endogenous noncoding RNAs that mediate the fibrotic process by regulating multiple targets. MicroRNA-based therapy can restore or inhibit miRNA expression and is expected to become an effective approach to prevent and alleviate fibrotic diseases. However, the safe, targeted, and effective delivery of miRNAs is a major challenge in translating miRNA therapy from bench to bedside. In this review, we briefly describe the pathophysiological process of fibrosis and the mechanism by which miRNAs regulate the progression of fibrosis. Additionally, we summarize the miRNA nanodelivery tools for fibrotic diseases, including chemical modifications and polymer-based, lipid-based, and exosome-based delivery systems. Further clarification of the role of miRNAs in fibrosis and the development of a novel nanodelivery system may facilitate the prevention and alleviation of fibrotic diseases in the future.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fibrosis
  • Humans
  • MicroRNAs* / metabolism
  • Polymers

Substances

  • MicroRNAs
  • Polymers